Cystic Fibrosis, CFTR Gene Variants, and Aspergillosis
Last reviewed: 8 April 2026
Some people with aspergillosis are told they have cystic fibrosis (CF), or that they carry a CFTR gene variant. This can be unexpected and may raise concerns about whether this explains their symptoms or diagnosis.
This article explains how cystic fibrosis and CFTR gene variants relate to Aspergillus-related lung disease, what current research shows, and—importantly—what conclusions should not be drawn.
Contents
- Key points
- Important reassurance
- What is cystic fibrosis?
- What is a CFTR gene variant?
- How CFTR affects the lungs
- How Aspergillus behaves in the lungs
- ABPA and cystic fibrosis
- CPA and cystic fibrosis
- Modern CF treatments and Aspergillus
- Does a CFTR variant explain symptoms?
- What should patients take from this?
- When to seek medical advice
- Conclusion
- References
Key points
- Most people with aspergillosis do not have cystic fibrosis.
- Most people with cystic fibrosis do not develop ABPA or CPA.
- ABPA is linked to mucus and immune responses, not just infection.
- CFTR variants may contribute to risk in some people, but are usually only one factor.
- CPA is mainly driven by structural lung damage, not CFTR genetics.
Important reassurance
Most people with aspergillosis do not have cystic fibrosis, and most people with cystic fibrosis do not develop Aspergillus-related disease.
Although these conditions can overlap, they are usually separate. Genetic findings such as CFTR variants should be interpreted carefully and in context.
What is cystic fibrosis?
Cystic fibrosis is a genetic condition caused by changes in the CFTR gene. This gene regulates salt and water movement across cells.
When CFTR function is reduced:
- mucus becomes thick and sticky
- airways are harder to clear
- microorganisms persist more easily
This creates an environment where bacteria and fungi can accumulate over time.
What is a CFTR gene variant?
CFTR variants range from severe mutations (causing cystic fibrosis) to mild or uncertain variants.
Carriers (with one variant):
- are common in the general population
- usually have no symptoms
- may have subtle effects in some cases
These subtle effects may include reduced mucus clearance or increased susceptibility to airway inflammation.
How CFTR affects the lungs
CFTR dysfunction affects the lungs in several key ways:
- Mucus dehydration: mucus becomes thick and difficult to clear
- Impaired clearance: particles and microbes remain in the airways
- Chronic inflammation: immune responses become exaggerated
This combination creates a “retention environment” where inhaled organisms—including Aspergillus—may persist.
How Aspergillus behaves in the lungs
Aspergillus is inhaled by everyone, but its effects vary depending on the lung environment.
- Healthy lungs: spores are cleared
- Impaired clearance: spores may persist
- Sensitive immune system: allergic reactions may develop
- Damaged lungs: chronic infection may develop
This explains why Aspergillus-related disease is diverse and depends heavily on underlying lung conditions.
ABPA and cystic fibrosis
ABPA is an allergic immune reaction to Aspergillus.
It is recognised in cystic fibrosis because:
- mucus retention increases exposure to Aspergillus
- immune responses can be exaggerated
However:
- Many CF patients never develop ABPA
- Most ABPA patients do not have CF
Some studies suggest CFTR variants may increase susceptibility, but this is not consistent across all research.
Key message: ABPA and CF can overlap, but one does not imply the other.
CPA and cystic fibrosis
CPA is a chronic fungal infection that develops in structurally damaged lungs.
The most important risk factor is:
pre-existing lung damage
This includes:
- bronchiectasis
- previous tuberculosis
- COPD
Cystic fibrosis can lead to bronchiectasis, and therefore indirectly increase CPA risk.
However:
- CPA is rarely driven directly by CFTR genetics
- most CPA patients do not have CF
Key message: CPA is primarily a disease of lung structure, not genetics.
Modern CF treatments and Aspergillus
CFTR modulators (such as elexacaftor/tezacaftor/ivacaftor) have transformed CF care.
They:
- improve CFTR function
- thin mucus
- improve clearance
Studies suggest:
- reduced Aspergillus detection in some patients
- fewer ABPA exacerbations in some cases
However:
- ABPA still occurs
- existing lung damage remains
- immune responses are not fully corrected
Overall: these therapies improve risk but do not eliminate Aspergillus-related disease.
Does a CFTR variant explain symptoms?
No single factor explains complex lung disease.
Symptoms may result from:
- underlying lung disease
- infection
- inflammation
- environmental exposure
A CFTR variant may contribute, but is rarely the sole cause.
What should patients take from this?
- CF and CFTR variants can sometimes contribute
- ABPA has the strongest connection
- CPA is mainly driven by lung damage
- Most patients with aspergillosis do not have CF
When to seek medical advice
Seek advice if symptoms worsen, change, or include coughing up blood, fever, or chest pain.
Conclusion
Cystic fibrosis and CFTR gene variants can play a role in some patients with Aspergillus-related lung disease, particularly where mucus clearance is affected. However, they should not be overemphasised. In most cases, they are just one part of a broader clinical picture involving lung structure, immune response, and environmental exposure.
References
- Miller PW et al. (1996)
- Marchand E et al. (2001)
- Eaton TE et al. (2002)
- Agarwal R et al. (2012)
- Chaudhary N et al. (2012)
- Warris A et al. (2019)
- Gamaletsou MN et al. (2018)
- Kosmidis C & Denning DW (2015)
- Moldoveanu B et al. (2021)
- Malik HS et al. (2025)
- Zeng C et al. (2025)
- Bendixen MP et al. (2025)
This article is for general information and does not replace advice from your clinical team.
Weekly Aspergillosis Research Update: 31 March – 7 April 2026
This week’s research reinforces several consistent themes in aspergillosis: ongoing diagnostic confusion (particularly with tuberculosis and cancer), increasing movement toward precision medicine, and continued development of both antifungal therapies and biomarkers. There is also a growing emphasis on host-pathogen interactions rather than fungal burden alone.
Key Highlights
- Isavuconazole levels can become unexpectedly high due to genetics and drug interactions.
- Chronic pulmonary aspergillosis (CPA) can mimic lung cancer, risking delayed diagnosis.
- New biomarker (EDN) for ABPA shows promise for diagnosis and monitoring.
- Azole resistance research highlights differences between Aspergillus species.
- New antifungal approaches emerging (olorofim, nitroxoline).
- Host response is central – fibroblasts and immune pathways actively influence disease.
- TB vs aspergillosis confusion persists in real-world settings.
Contents
- Clinical & Diagnostic Studies
- Treatment & Pharmacology
- Biology, Immunology & Resistance
- Biomarkers & Diagnostics
- Wider Context
Clinical & Diagnostic Studies
CPA mistaken for lung cancer
Paper: PubMed
A case report describes chronic pulmonary aspergillosis presenting as suspected lung malignancy in a patient with asthma and ABPA overlap.
Why this matters: CPA continues to be misdiagnosed due to tumour-like imaging appearances. This reinforces the need to consider fungal disease in patients with underlying lung conditions.
Invasive sinus aspergillosis causing bone destruction
Paper: Free full text
Granulomatous invasive aspergillosis led to facial bone destruction and neurological symptoms.
Why this matters: Delayed diagnosis of invasive disease can lead to severe structural damage. Early imaging and specialist input are critical.
Aspergillus infection in suspected TB patients
Paper: PubMed
Study shows overlap between tuberculosis and aspergillosis in symptomatic patients.
Why this matters: Persistent global issue—shared symptoms delay correct diagnosis and treatment, particularly relevant for CPA pathways.
Invasive aspergillosis in critical illness
Paper: PubMed
Case of invasive pulmonary aspergillosis in a patient with severe viral illness.
Why this matters: Reinforces that aspergillosis is not limited to traditional risk groups and can complicate severe systemic illness.
Treatment & Pharmacology
Isavuconazole toxicity linked to genetics
Paper: Free full text
Case report of supratherapeutic isavuconazole levels linked to CYP3A5 genotype and interacting medications.
Why this matters: Even “predictable” antifungals show variability. Supports therapeutic drug monitoring and future personalised dosing approaches.
Olorofim pharmacokinetics
Paper: PubMed
Study demonstrates tissue distribution of olorofim in preclinical models.
Why this matters: Supports ongoing development of a key next-generation antifungal, particularly for resistant disease.
Nitroxoline shows antifungal activity
Paper: PubMed
Repurposed drug demonstrates activity against Aspergillus via copper disruption and oxidative stress.
Why this matters: Highlights potential for non-azole antifungal strategies in future treatment.
Biology, Immunology & Resistance
Azole resistance and Aspergillus genomics
Paper: PubMed
Genomic study of Aspergillus section Fumigati explores resistance mechanisms and pathogenicity.
Why this matters: Different species may respond differently to antifungals—accurate identification is increasingly important.
Fibroblasts actively support lung defence
Paper: PubMed
Study shows fibroblasts contribute to immune defence and tissue repair during infection.
Why this matters: Disease outcomes depend on host response, not just fungal burden—important for future therapies.
Immune pathway targeting in fungal keratitis
Paper: PubMed
PIM1 inhibition reduces inflammation via STING pathway signalling.
Why this matters: Supports growing interest in targeting immune pathways alongside antifungal therapy.
Biomarkers & Diagnostics
Eosinophil-derived neurotoxin (EDN) in ABPA
Paper: PubMed
EDN proposed as a biomarker for allergic bronchopulmonary aspergillosis.
Why this matters: Could improve diagnosis and monitoring, helping distinguish ABPA from asthma or sensitisation alone.
Commentary on ISHAM ABPA guidelines
Paper: PubMed
Discussion of updated international guidance on ABPA diagnosis and management.
Why this matters: Highlights ongoing refinement of diagnostic criteria and classification systems.
Wider Context
Fungal extracellular vesicles
Paper: PubMed
Review of fungal vesicles in pathogenesis and host interaction.
Why this matters: Emerging area that may influence future diagnostics and therapies.
Aspergillosis in broader disease settings
Why this matters: Aspergillosis continues to appear across a wide range of conditions, particularly in critically ill or immunocompromised patients.
Overall Interpretation
This week’s literature reinforces several strategic priorities:
- Earlier and more accurate diagnosis remains essential, particularly in distinguishing CPA from TB and cancer.
- Precision medicine is advancing, with growing roles for pharmacogenomics, drug monitoring, and species-level identification.
- New antifungal options are progressing, but remain largely in development.
- Host response is increasingly recognised as central to disease progression and outcomes.
Overall, the field continues to move toward more personalised, biology-driven approaches to diagnosis and management.
Voriconazole interactions: what patients need to know
Key points
- Voriconazole interacts with many medicines.
- It affects several liver enzyme pathways, including CYP3A4, CYP2C19, and CYP2C9.
- Its behaviour can vary more from one person to another than some other azoles.
- Some medicines can make voriconazole stronger, while others can make it less effective.
- Visual side effects and sensitivity to sunlight are well recognised with voriconazole.
What is voriconazole?
Voriconazole is an azole antifungal often used in serious fungal infections, including aspergillosis. It can be very effective, but it also has a relatively complex interaction profile.
Why voriconazole interacts with so many medicines
Voriconazole affects several liver enzyme systems, including CYP3A4, CYP2C19, and CYP2C9. It can increase the levels of some medicines, while some other medicines can lower voriconazole levels and reduce its effectiveness.
Because voriconazole metabolism varies between patients, the same combination can affect people differently.
The interaction groups most likely to matter
Steroids
Voriconazole can increase exposure to some steroids, including inhaled steroids, which may increase the risk of steroid side effects.
Medicines that reduce voriconazole levels
Some medicines, including certain anti-seizure medicines and rifampicin-type antibiotics, can reduce voriconazole levels so much that the antifungal may not work properly.
Blood thinners
Some blood thinners may become stronger when taken with voriconazole, increasing bleeding risk.
Heart rhythm medicines
Voriconazole can contribute to QT prolongation, so combinations with other medicines that affect heart rhythm may be particularly important.
Statins
Some statins can become stronger when taken with voriconazole, increasing the risk of muscle side effects.
Immunosuppressants
Medicines such as tacrolimus and ciclosporin can rise significantly with voriconazole and often require specialist monitoring and dose adjustment.
Sedatives and some mental health medicines
Some sedatives and psychiatric medicines can become stronger when combined with voriconazole, increasing the risk of drowsiness, confusion, or other side effects.
Voriconazole-specific issues patients should know
Visual changes
Temporary visual disturbances are well recognised with voriconazole. Patients may notice blurred vision, brighter vision, or changes in colour perception.
Photosensitivity
Voriconazole can increase sensitivity to sunlight. Patients should use sensible sun protection and report new skin changes, especially during long-term treatment.
Variable drug levels
Voriconazole levels can vary between patients, which is one reason some teams use therapeutic drug monitoring in selected situations.
What patients should do in practice
- Tell your clinical team and pharmacist that you are taking voriconazole.
- Check before starting new medicines, including over-the-counter or herbal products.
- Report visual changes, significant sensitivity to sunlight, or a change in symptoms after a medicine change.
- Do not change treatment without advice.
When to seek medical advice
Seek medical advice urgently for severe bleeding, fainting, severe palpitations, marked confusion, or rapid worsening after a medicine change.
Important
This page is educational and does not list every interaction. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.
References
Itraconazole interactions: what patients need to know
Key points
- Itraconazole can interact with many other medicines.
- It usually does this by affecting liver enzymes, especially CYP3A4.
- Some combinations need careful monitoring, while others are best avoided.
- Capsules and liquid formulations are not handled by the body in exactly the same way.
- This page highlights the interactions most likely to matter to people with aspergillosis.
What is itraconazole?
Itraconazole is an azole antifungal used in aspergillosis and other fungal infections. It has a relatively high interaction burden, so medicine checks are especially important before starting it and whenever another medicine is added, stopped, or changed.
Why itraconazole interacts with so many medicines
Itraconazole can increase the levels of some other medicines by affecting liver enzymes, especially CYP3A4. This means that some medicines may become stronger than intended, which can increase the risk of side effects or toxicity.
The interaction groups most likely to matter
Steroids and inhalers
This is one of the most important groups for many aspergillosis patients, especially those with asthma or allergic bronchopulmonary aspergillosis. Itraconazole can increase exposure to some steroids, including inhaled steroids, which may increase the risk of steroid side effects.
Possible symptoms to report: unusual weight gain, easy bruising, increased facial rounding, mood changes, worsening blood sugar control, weakness, or marked fatigue.
Statins
Some statins can become much stronger when taken with itraconazole. This can increase the risk of muscle toxicity.
Possible symptoms to report: new muscle pain, muscle weakness, or dark urine.
Blood thinners
Itraconazole can increase the effect of some blood thinners, which may raise bleeding risk.
Possible symptoms to report: unusual bruising, bleeding that is hard to stop, black stools, vomiting blood, or coughing up much more blood than usual.
Heart and rhythm medicines
Some combinations can increase the risk of serious heart rhythm problems. Itraconazole is also used cautiously in people with a history of ventricular dysfunction or heart failure unless the infection is serious.
Possible symptoms to report: fainting, palpitations, marked dizziness, increasing ankle swelling, or worsening breathlessness.
Sleeping tablets, sedatives, and some mental health medicines
Some sedatives and psychotropic medicines can become stronger when combined with itraconazole, increasing the risk of drowsiness, confusion, falls, or breathing problems.
Immunosuppressants
Medicines such as tacrolimus and ciclosporin can rise significantly when taken with itraconazole and usually need specialist monitoring.
Medicines that can make itraconazole less effective
Some medicines lower itraconazole levels, which means the antifungal may not work as well. This can happen with some anti-seizure medicines, rifampicin-type antibiotics, and some antiviral medicines.
Acid-reducing medicines and itraconazole capsules
Reduced stomach acid can lower the absorption of itraconazole capsules. This means reflux medicines, antacids, and some acid-suppressing treatments can affect how well the capsules work. The liquid formulation behaves differently and should not be treated as interchangeable with capsules.
What patients should do in practice
- Keep a current medicines list and bring it to appointments.
- Tell clinicians and pharmacists if you are taking itraconazole.
- Ask specifically about inhalers, steroid tablets, statins, blood thinners, and reflux treatment.
- Do not change doses or stop medicines without advice.
- If your itraconazole formulation changes, ask whether it should be taken with food or on an empty stomach.
When to seek medical advice
Seek urgent medical advice for severe bleeding, black stools, vomiting blood, severe muscle pain, fainting, marked palpitations, or rapidly worsening breathlessness.
Important
This page is not a full interaction database. For a complete medicine-by-medicine check, use the BNF interaction checker or speak to a pharmacist or clinician.
References
Amphotericin B interactions: what patients need to know
Key points
- Amphotericin B comes in different formulations, and they are not interchangeable.
- Its main interaction risks are different from the azoles.
- The most important problems are usually kidney stress, low potassium, low magnesium, and additive toxicity with other medicines.
- These risks matter most with intravenous treatment.
- If you hear “amphotericin B”, it is important to know which formulation is being used.
What is amphotericin B?
Amphotericin B is an antifungal used mainly for serious fungal infections. In modern UK practice this often means liposomal amphotericin B, but conventional amphotericin B deoxycholate is also a recognised formulation.
Why amphotericin B interactions are different from azoles
Unlike azole antifungals, amphotericin B does not mainly cause medicine interactions through liver enzymes. Its most important interaction risks usually relate to kidney injury, low potassium, low magnesium, and infusion-related effects.
The interaction groups most likely to matter
Other medicines that can damage the kidneys
This is one of the most important groups. Combining amphotericin B with other nephrotoxic medicines can increase the risk of kidney injury.
Diuretics, steroids, and other medicines that lower potassium
Amphotericin B can lower potassium, and some other medicines can make this worse. This may increase the risk of weakness, cramps, or heart rhythm problems.
Digoxin and heart-rhythm-sensitive situations
Low potassium caused by amphotericin B can make digoxin-related toxicity more likely and may increase the importance of electrolyte monitoring.
Flucytosine
When combined with flucytosine, specialist monitoring may be needed because toxicity can increase.
Some cancer medicines and intensive hospital treatments
In hospital, additive toxicity with other intensive treatments may be particularly important, especially where kidneys and electrolytes are already under strain.
White blood cell transfusions
Acute lung reactions are a recognised specialist concern if amphotericin B is given during or soon after leukocyte transfusions.
Why the formulations matter
Amphotericin B formulations are not interchangeable. Conventional amphotericin B deoxycholate and liposomal amphotericin B have different dosing, different handling by the body, and different safety profiles. Using the wrong formulation in the wrong dose has caused serious and even fatal errors.
In general, liposomal amphotericin B is less nephrotoxic than conventional amphotericin B deoxycholate, but it still requires careful monitoring.
What patients should do in practice
- Ask which amphotericin B formulation is being used.
- Tell the clinical team about all medicines, especially kidney-risk medicines, diuretics, steroids, and digoxin.
- Expect blood tests to monitor kidney function, potassium, and magnesium during intravenous treatment.
- Report weakness, reduced urine output, worsening swelling, palpitations, or marked dizziness.
When to seek medical advice
Seek urgent medical help for severe breathlessness, fainting, major palpitations, or a rapid deterioration during treatment.
Important
This page is educational and does not list every possible interaction. Amphotericin B treatment is usually managed by specialist teams, especially when given intravenously.
References
Isavuconazole interactions: what patients need to know
Key points
- Isavuconazole can interact with other medicines, but its interaction profile is often less complex than older azoles.
- It mainly interacts through CYP3A4.
- Some medicines can increase isavuconazole levels, while others can reduce its effectiveness.
- It has an important difference from some other azoles: it can shorten the QT interval.
- It is still essential to check new medicines carefully.
What is isavuconazole?
Isavuconazole is a newer azole antifungal used in invasive aspergillosis and some other serious fungal infections. It is often seen as having a more predictable interaction profile than some older azoles, but it still has important interactions.
Why isavuconazole interacts with other medicines
Isavuconazole is mainly linked to CYP3A4. This means some medicines can become stronger when combined with it, while other medicines can lower isavuconazole levels and reduce its effectiveness.
The interaction groups most likely to matter
Medicines that reduce isavuconazole effectiveness
Some medicines, including rifampicin-type antibiotics and certain anti-seizure drugs, can lower isavuconazole levels and may make treatment ineffective.
Steroids
Some steroid levels may rise with isavuconazole, although the interaction pattern is often less intense than with some older azoles.
Immunosuppressants
Medicines such as tacrolimus and ciclosporin may increase and usually need specialist review and monitoring.
Blood thinners
Some blood thinners may become stronger, increasing bleeding risk.
Statins
Some statin levels may increase, which can raise the risk of muscle side effects.
Important isavuconazole-specific points
QT shortening
Unlike several other azole antifungals, isavuconazole can shorten the QT interval. This is an important difference and should be considered when other heart medicines are being reviewed.
Generally simpler interaction profile
Compared with itraconazole and voriconazole, isavuconazole is often considered a little easier to manage in patients taking several medicines, although checks are still essential.
What patients should do in practice
- Tell your pharmacist or clinician if you are taking isavuconazole.
- Check before starting prescription, over-the-counter, or herbal medicines.
- Ask specifically about anti-seizure drugs, antibiotics, blood thinners, and heart medicines.
- Do not stop or change medicines without advice.
When to seek medical advice
Seek medical advice urgently for severe bleeding, fainting, severe palpitations, severe muscle pain, or rapid worsening after a medicine change.
Important
This page is educational and not a complete interaction database. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.
References
- BNF: isavuconazole monograph and interactions
- UK isavuconazole SmPCs - not available
Posaconazole interactions: what patients need to know
Key points
- Posaconazole can interact with other medicines, although its interaction pattern is often a little simpler than itraconazole or voriconazole.
- It mainly interacts through CYP3A4 inhibition.
- Important interaction groups include immunosuppressants, steroids, blood thinners, and some heart medicines.
- Some medicines can reduce posaconazole levels and make treatment less effective.
- Tablets and oral suspension are not interchangeable in the same way.
What is posaconazole?
Posaconazole is an azole antifungal used in aspergillosis and in some high-risk patients for prevention of fungal infection. It is often seen as somewhat easier to manage than some older azoles, but important interactions still exist.
Why posaconazole interacts with other medicines
Posaconazole mainly affects CYP3A4, a key liver enzyme involved in handling many medicines. This means some drugs can become stronger, while some combinations can lower posaconazole levels and make it less effective.
The interaction groups most likely to matter
Steroids
Posaconazole can increase exposure to some steroids, including inhaled or oral steroids, which may increase the risk of steroid side effects.
Immunosuppressants
Medicines such as tacrolimus and ciclosporin can rise significantly with posaconazole and usually need close specialist monitoring.
Blood thinners
Some blood thinners may become stronger, increasing bleeding risk.
Statins
Some statins can rise in level, increasing the risk of muscle problems.
Heart rhythm medicines
Some combinations can increase the risk of heart rhythm problems and need careful review.
Medicines that reduce posaconazole effectiveness
Some medicines, including rifampicin-type antibiotics and certain anti-seizure drugs, can lower posaconazole levels and may make treatment less effective.
Posaconazole formulations and absorption
Posaconazole comes in different forms, including tablets, oral suspension, and infusion. The oral suspension and tablets are not handled identically by the body and should not be assumed to be interchangeable dose-for-dose without clinical advice.
In practice, the tablets tend to be more predictable than the suspension.
What patients should do in practice
- Tell your pharmacist or clinician if you are taking posaconazole.
- Ask about new medicines, especially blood thinners, steroids, statins, and heart medicines.
- If your formulation changes, ask whether there are any special instructions.
- Do not stop or swap medicines without advice.
When to seek medical advice
Seek medical advice urgently for severe bleeding, fainting, major palpitations, severe muscle pain, or rapid worsening after a medicine change.
Important
This page does not list every interaction. For a full check, use the BNF interaction checker or speak to a pharmacist or clinician.
References
Antifungal drug interactions: what patients with aspergillosis need to know
Key points
- Antifungal medicines can interact with other medicines, including inhalers, steroid tablets, blood thinners, heart medicines, cholesterol tablets, and some over-the-counter or herbal products.
- The azole antifungals usually interact by affecting how the liver handles medicines.
- Amphotericin B is different: its main interaction risks are more often linked to kidneys, potassium, magnesium, and infusion-related effects.
- This page gives an overview. It does not list every interaction.
- For a full medicine-by-medicine check, use the BNF interaction checker or ask a pharmacist or clinician.
Why interactions matter in aspergillosis
People with aspergillosis often take more than one medicine. This may include inhalers, steroid tablets, medicines for reflux, antibiotics, pain relief, blood pressure treatment, blood thinners, cholesterol tablets, and drugs for other long-term conditions. That means medicine checks are especially important whenever an antifungal is started, stopped, or changed.
How the main antifungals differ
Most long-term interaction questions in aspergillosis involve the azole antifungals: itraconazole, voriconazole, posaconazole, and isavuconazole. These mainly interact because they affect liver enzymes, especially CYP3A4, although some also affect CYP2C9 and CYP2C19.
Amphotericin B behaves differently. Its most important risks are usually kidney stress, low potassium, low magnesium, and additive toxicity with other medicines rather than classic liver-enzyme interactions.
Quick comparison table
| Antifungal | Main interaction pattern | Typical complexity | Important extra point |
|---|---|---|---|
| Itraconazole | Strong enzyme-based interactions, especially CYP3A4 | High | Capsules and liquid are not handled by the body in the same way |
| Voriconazole | Complex enzyme-based interactions involving several CYP pathways | High | More variable between patients; visual side effects and photosensitivity are well recognised |
| Posaconazole | Mainly CYP3A4-related interactions | Moderate | Tablets and oral suspension are not interchangeable in the same way |
| Isavuconazole | Mainly CYP3A4-related interactions, usually less complex than older azoles | Lower to moderate | Can shorten the QT interval |
| Amphotericin B | Kidney, potassium, magnesium, and infusion-related interaction risks | Different rather than simpler | Formulations are not interchangeable |
Individual antifungal guides
- Itraconazole interactions: what patients need to know
- Voriconazole interactions: what patients need to know
- Posaconazole interactions: what patients need to know
- Isavuconazole interactions: what patients need to know
- Amphotericin B interactions: what patients need to know
What patients should do in practice
- Keep an up-to-date list of all medicines, including inhalers, creams, over-the-counter medicines, supplements, and herbal products.
- Tell your doctor, nurse, pharmacist, or hospital team that you are taking an antifungal.
- Do not start, stop, or swap medicines on your own because of something you have read online.
- Ask specifically about new medicines, steroid changes, reflux treatment, blood thinners, cholesterol medicines, and heart medicines.
When to seek medical advice
Seek medical advice promptly if symptoms change after a medicine is started, stopped, or changed. Seek urgent help for severe bleeding, fainting, severe muscle pain, marked palpitations, rapidly worsening breathlessness, severe drowsiness, or a sudden significant decline in your health.
Important
This resource is educational. It does not replace personalised advice from your clinical team, GP, or pharmacist, and it is not a complete interaction database.
References
Why Aspergillosis Is So Hard to Diagnose
Last reviewed: 18 March 2026
Key points
- Aspergillosis is often difficult to diagnose because its symptoms can look very similar to those of more common conditions.
- Diagnosis usually depends on several pieces of evidence being brought together, rather than one simple test.
- Doctors are trained to consider common conditions first, because this is usually the safest and most efficient approach.
- This approach works well for many patients, but it can delay recognition of conditions such as aspergillosis.
- Delays are often caused by the way healthcare systems are organised, not by lack of care or effort from individual clinicians.
- Patients can help by keeping a clear record of symptoms, tests, treatments, and how things have changed over time.
Why diagnosis can be difficult
Aspergillosis is not a single illness but a group of conditions caused by Aspergillus, a mould commonly found in the environment. These include:
- Allergic bronchopulmonary aspergillosis (ABPA)
- Chronic pulmonary aspergillosis (CPA)
- Other airway and colonisation-related conditions
Diagnosis usually depends on combining:
- symptoms over time
- CT scan findings
- blood tests (including immunological tests)
- sputum microbiology
- clinical history
There is rarely a single “yes or no” test, which is why diagnosis can take time.
What the patient journey often looks like
Early symptoms
Symptoms such as cough, breathlessness, fatigue, or sputum are common across many conditions including bronchiectasis, asthma, and infection.
Treatment for common conditions
Initial treatment often includes antibiotics, inhalers, or steroids. These are appropriate first steps based on clinical guidelines such as those from the British Thoracic Society (BTS).
Ongoing symptoms
When symptoms persist or return, further investigation is usually needed.
The turning point
At some stage, fungal disease may be considered and tests for Aspergillus are performed.
Why doctors tackle common conditions first
Why do doctors start with common conditions?
Doctors treat common diseases first, prioritizing efficiency, patient safety, and high-probability outcomes. This approach, considering the most likely diagnosis first, helps manage patient health efficiently and effecctively before investigating rare or complex conditions.
This approach is safe and effective for most people, but conditions like aspergillosis can sit outside these usual pathways.
Where delays can happen
Overlap of symptoms
Symptoms overlap with many conditions, including tuberculosis and lung cancer.
No single definitive test
Diagnosis often requires combining multiple test results rather than relying on one.
Gradual disease progression
Conditions such as CPA may evolve over months or years.
Multiple conditions
Patients may have more than one lung condition at the same time.
Why this is often about the system, not the individual doctor
Healthcare systems are designed to manage large numbers of patients efficiently and safely. This means prioritising common conditions first.
However, aspergillosis often requires specialist input. In the UK, this may include referral to the National Aspergillosis Centre, which provides expert assessment and management.
International guidance from organisations such as ESCMID (European Society of Clinical Microbiology and Infectious Diseases) also highlights the complexity of fungal diseases.
What patients can do
- Keep a record of symptoms and treatments
- Ask when diagnosis should be reviewed
- Discuss whether further tests are needed
- Use trusted information sources such as our diagnosis guide
A more balanced way to think about delay
Diagnosis is often not a single event but a process that unfolds over time.
The goal is to recognise patterns earlier and ensure patients who need specialist input are identified sooner.
Common questions
Why was I treated for other conditions first?
Because those conditions are more common and more likely.
Should I ask about aspergillosis?
Yes, especially if symptoms are persistent or unusual—but it should be part of a broader discussion.
When to seek medical advice
- Persistent or worsening symptoms
- Coughing up blood
- Unexplained weight loss
References and further reading
National Aspergillosis Centre, Antifungal Therapeutic Drug Monitoring (TDM), Molecular Resistance Testing & Antimicrobial Stewardship
How the National Aspergillosis Centre Supports UK Clinicians
Long-term antifungal therapy in aspergillosis presents a distinct antimicrobial stewardship (AMS) challenge. Treatment is often prolonged, drug exposure is highly variable, and resistance may emerge during therapy.
The National Aspergillosis Centre (NAC), working closely with the Mycology Reference Centre Manchester (Manchester UK"], provides national expertise through:
-
Therapeutic drug monitoring (TDM)
-
Molecular resistance testing
-
Specialist Advice & Guidance
-
Remote multidisciplinary team (MDT) review
-
Standardised laboratory processes
Together, these services enable UK clinicians to optimise antifungal therapy while aligning with national AMS strategy and antimicrobial resistance (AMR) policy.
The National AMS Framework: Why This Matters
Antifungal stewardship sits within the wider UK antimicrobial resistance strategy.
Key national resources include:
1️⃣ NHS England – Digital Vision for Antimicrobial Stewardship
https://www.england.nhs.uk/long-read/digital-vision-for-antimicrobial-stewardship-in-england/
Emphasises:
-
Data-driven optimisation
-
Decision support
-
Clear documentation
-
Measurable stewardship interventions
2️⃣ Antimicrobial Prescribing & Stewardship Competency Framework
https://www.gov.uk/government/publications/antimicrobial-prescribing-and-stewardship-competencies
Defines clinician responsibilities including:
-
Right drug
-
Right dose
-
Right duration
-
Monitoring for toxicity
-
Review and stop decisions
3️⃣ English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR)
Supports:
-
National resistance monitoring
-
Stewardship benchmarking
-
Reduction of inappropriate antimicrobial exposure
4️⃣ Chronic Pulmonary Aspergillosis (CPA) Service Specification
https://www.england.nhs.uk/publication/chronic-pulmonary-aspergillosis-service-adults/
This specialised service model explicitly includes:
-
Optimisation of antifungal therapy
-
Toxicity monitoring
-
Therapeutic drug monitoring
Antifungal stewardship is embedded within the commissioned service design.
Why Aspergillosis Requires Enhanced Stewardship
Unlike short-course antibacterial therapy, aspergillosis often involves:
-
Long-term triazole therapy
-
Structural lung disease
-
High interaction burden
-
Emerging environmental resistance
-
Potential for treatment failure despite adequate adherence
Effective stewardship therefore requires both:
-
Assurance of adequate drug exposure (TDM)
-
Assurance of organism susceptibility (molecular testing)
1️⃣ Therapeutic Drug Monitoring (TDM)
Triazole antifungals demonstrate:
-
High pharmacokinetic variability
-
Concentration-dependent toxicity
-
Reduced efficacy if under-dosed
TDM enables:
✔ Early detection of subtherapeutic exposure
✔ Prevention of toxicity
✔ Dose optimisation
✔ Reduction of avoidable escalation
This directly fulfils AMS competency expectations.
2️⃣ Molecular Resistance Testing
Azole resistance in Aspergillus fumigatus is increasingly recognised in the UK.
Through MRCM, NAC supports:
CYP51A Mutation Analysis
Common mutations include:
-
TR34/L98H
-
TR46/Y121F/T289A
These may arise:
-
Environmentally (azole fungicide pressure)
-
During long-term therapy
Phenotypic Susceptibility Testing
Where viable isolates are available:
-
Minimum inhibitory concentration (MIC) testing
-
Clinical interpretation to guide therapy
Why Resistance Testing Is Essential for AMS
If a patient deteriorates despite adequate serum levels:
-
Continuing the same azole is not stewardship
-
Escalating empirically without evidence increases antimicrobial pressure
Molecular confirmation ensures:
✔ Rational switching
✔ Avoidance of ineffective therapy
✔ Contribution to national resistance surveillance
This aligns with ESPAUR and national AMR objectives.
3️⃣ Remote Advice & Guidance & MDT Review
The NAC provides structured national clinician support.
This strengthens stewardship by:
✔ Refining diagnosis
✔ Preventing indication drift
✔ Setting defined review points
✔ Supporting stop decisions
✔ Reducing empirical prolonged therapy
Early specialist review is one of the most effective stewardship interventions.
Integrated Stewardship Model
| Clinical Situation | TDM | Molecular Testing |
|---|---|---|
| Initiation of azole | Yes | Not routine |
| Poor response + low level | Adjust dose | Not primary |
| Poor response + adequate level | Confirm exposure | Essential |
| Long-term therapy | Periodic monitoring | Consider if progression |
| Relapse on therapy | Check level | Strongly consider |
Exposure optimisation + susceptibility confirmation = complete antifungal stewardship.
Practical Workflow for UK Teams
Step 1 – Define Indication
-
Syndrome
-
Treatment objective
-
Planned review date
Step 2 – Baseline Safety Checks
-
Interaction review
-
Liver function tests
-
ECG where appropriate
Step 3 – Perform TDM
Include:
-
Drug
-
Dose
-
Time of last dose
-
Time of sampling
Step 4 – If Clinical Failure Occurs
-
Confirm adequate drug exposure
-
Consider molecular resistance testing
Step 5 – Define Stop/Review Criteria
Avoid open-ended therapy without documented reassessment.
Demonstrating AMS Compliance in Practice
Using NAC-supported services allows Trusts to evidence:
✔ Documented indication
✔ Dose optimisation
✔ Toxicity mitigation
✔ Rational escalation
✔ Defined review intervals
✔ Resistance surveillance contribution
✔ Specialist consultation
This is measurable, defensible antimicrobial stewardship.
Conclusion
Antifungal stewardship in aspergillosis cannot rely on restriction alone.
It requires:
-
Precision dosing
-
Genetic resistance detection
-
Structured specialist review
-
Alignment with national AMS frameworks
Through integrated therapeutic drug monitoring, molecular resistance testing, and national clinical support, the National Aspergillosis Centre provides a UK model for precision antifungal stewardship aligned with national antimicrobial resistance strategy.